Is the NADAC floor what my PBM actually charges me?

No. NADAC is the average price retail pharmacies pay wholesalers (published weekly by CMS). It is not what your PBM bills your plan. Your PBM cost is set by your contract, typically AWP-X% with a MAC list overlay on generics. The gap between NADAC and PBM-billed cost is called spread — commonly 100-400% on generics on legacy contracts.

Does this account for the rebates I would lose by switching off brand?

No — the opportunity column is gross of rebates. When you move a brand molecule to a lower tier or push toward generics, you lose the brand rebate flow that offset gross spend. Year-1 typical realization is 30-60% of gross opportunity; year-2 approaches gross as utilization migrates.

Leak Report — Score Your Drug List Against Federal Data

Drop your drugs. We'll show the spread.

Built for the PBM renewal conversation. Paste your top drugs, your full formulary, or your top-25 by spend — we cross-reference against CMS NADAC, FDA Orange Book ANDA filings, Part D formulary tier placement across 329 plans, and CMS Part D claim-level utilization, then rank by gross savings opportunity before rebates.

01Your input

Paste the drugs you actually spend money on.

One drug per line. Generic name, brand name, or NDC — we match all three. Combination products are best entered as the brand name. The pre-filled list is a top-spend Part D sample to demo the tool; replace with yours.

15 drugs on your list Live NADAC + Part D CY24 · matched against rxfinder.ai's 3,186-drug universe

Use sample: cardiovascular· behavioral health· top-25 Part D

02Your plan

Three numbers shape the answer.

Covered lives scales the opportunity to your book. Minimum spend filters out molecules too small to move. Minimum generic manufacturer count filters out drugs where competitive pricing doesn't yet exist.

Covered lives

lives

Active Part D members in scope.

Min annual spend (Part D)

Filter out small-spend molecules.

Min generic manufacturers

mfrs

Below this, competitive pricing isn't reliable.

Run leak report against federal data —

→

03The report

Where the money actually is.

Ranked by gross annualized opportunity per your covered-life count. "Opportunity" is the dollar delta between average current NADAC and lowest available NADAC across the molecule's NDCs, scaled by Part D claim volume. Numbers are pre-rebate — see Q&A below on how to net.

Drugs scored

—of — on your list

Meet leak criteria

—after your filters applied

Total opportunity

—per your covered lives · pre-rebate

Sort by

Click "Run leak report" above to score your list against federal data.

Sources: CMS NADAC weekly · CMS Part D Spending CY24 · FDA Orange Book ANDA filings

Drop your drugs. We'll show the spread.

Paste the drugs you actually spend money on.

Three numbers shape the answer.

Where the money actually is.

What this report does and doesn't tell you.